These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 32816294)

  • 1. [Psychedelics for existential distress in terminally ill patients].
    Schimmel N; Breeksema JJ; Veraart JKE; van den Brink W; Schoevers RA
    Tijdschr Psychiatr; 2020; 62(8):659-668. PubMed ID: 32816294
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Psychedelics for the treatment of depression, anxiety, and existential distress in patients with a terminal illness: a systematic review.
    Schimmers N; Breeksema JJ; Smith-Apeldoorn SY; Veraart J; van den Brink W; Schoevers RA
    Psychopharmacology (Berl); 2022 Jan; 239(1):15-33. PubMed ID: 34812901
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Classical psychedelics for the treatment of depression and anxiety: A systematic review.
    Muttoni S; Ardissino M; John C
    J Affect Disord; 2019 Nov; 258():11-24. PubMed ID: 31382100
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Psychedelics in the treatment of depression, anxiety, and obsessive-compulsive disorder].
    Breeksema JJ; van den Brink W; Veraart JKE; Smith-Apeldoorn SY; Vermetten E; Schoevers RA
    Tijdschr Psychiatr; 2020; 62(8):618-628. PubMed ID: 32816290
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic Applications of Classic Hallucinogens.
    Bogenschutz MP; Ross S
    Curr Top Behav Neurosci; 2018; 36():361-391. PubMed ID: 28512684
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function.
    Johnson MW; Hendricks PS; Barrett FS; Griffiths RR
    Pharmacol Ther; 2019 May; 197():83-102. PubMed ID: 30521880
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of Psychedelics in Treatment-Resistant Depression.
    Kamal S; Jha MK; Radhakrishnan R
    Psychiatr Clin North Am; 2023 Jun; 46(2):291-305. PubMed ID: 37149346
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Efficacy of psychedelics in psychiatry, a systematic review of the literature].
    Berkovitch L; Roméo B; Karila L; Gaillard R; Benyamina A
    Encephale; 2021 Aug; 47(4):376-387. PubMed ID: 33888297
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Taking Psychedelics Seriously.
    Byock I
    J Palliat Med; 2018 Apr; 21(4):417-421. PubMed ID: 29356590
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy, tolerability, and safety of serotonergic psychedelics for the management of mood, anxiety, and substance-use disorders: a systematic review of systematic reviews.
    Dos Santos RG; Bouso JC; Alcázar-Córcoles MÁ; Hallak JEC
    Expert Rev Clin Pharmacol; 2018 Sep; 11(9):889-902. PubMed ID: 30102078
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic use of classic psychedelics to treat cancer-related psychiatric distress.
    Ross S
    Int Rev Psychiatry; 2018 Aug; 30(4):317-330. PubMed ID: 30102082
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Post-acute psychological effects of classical serotonergic psychedelics: a systematic review and meta-analysis.
    Goldberg SB; Shechet B; Nicholas CR; Ng CW; Deole G; Chen Z; Raison CL
    Psychol Med; 2020 Dec; 50(16):2655-2666. PubMed ID: 33143790
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial.
    Ross S; Bossis A; Guss J; Agin-Liebes G; Malone T; Cohen B; Mennenga SE; Belser A; Kalliontzi K; Babb J; Su Z; Corby P; Schmidt BL
    J Psychopharmacol; 2016 Dec; 30(12):1165-1180. PubMed ID: 27909164
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cessation and reduction in alcohol consumption and misuse after psychedelic use.
    Garcia-Romeu A; Davis AK; Erowid F; Erowid E; Griffiths RR; Johnson MW
    J Psychopharmacol; 2019 Sep; 33(9):1088-1101. PubMed ID: 31084460
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Classic Psychedelics in Addiction Treatment: The Case for Psilocybin in Tobacco Smoking Cessation.
    Johnson MW
    Curr Top Behav Neurosci; 2022; 56():213-227. PubMed ID: 35704271
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Are psychedelic medicines the reset for chronic pain? Preliminary findings and research needs.
    Zia FZ; Baumann MH; Belouin SJ; Dworkin RH; Ghauri MH; Hendricks PS; Henningfield JE; Lanier RK; Ross S; Berger A
    Neuropharmacology; 2023 Aug; 233():109528. PubMed ID: 37015315
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Psychedelics in the treatment of PTSD].
    Vermetten E; Krediet E; Bostoen T; Breeksema JJ; Schoevers RA; van den Brink W
    Tijdschr Psychiatr; 2020; 62(8):640-649. PubMed ID: 32816292
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessing the effects of methodological differences on outcomes in the use of psychedelics in the treatment of anxiety and depressive disorders: A systematic review and meta-analysis.
    Leger RF; Unterwald EM
    J Psychopharmacol; 2022 Jan; 36(1):20-30. PubMed ID: 34519567
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Illicit use of LSD or psilocybin, but not MDMA or nonpsychedelic drugs, is associated with mystical experiences in a dose-dependent manner.
    Lyvers M; Meester M
    J Psychoactive Drugs; 2012; 44(5):410-7. PubMed ID: 23457892
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Psychedelic medicines for end-of-life care: Pipeline clinical trial review 2022.
    Jing X; Hoeh NR; Menkes DB
    Palliat Support Care; 2023 Aug; 21(4):697-704. PubMed ID: 37334486
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.